1. "GSK Faculty"
Formats
  1. Journal Article (13834)
  2. Meeting Abstract (7078)
  3. Review (514)
  4. Book Section (342)
  5. Editorial (307)
  6. Conference Paper (162)
  7. Research Letter (96)
  8. Miscellaneous (45)
  9. Correspondence (38)
  10. Guidelines (32)
  11. Book Whole (22)
Groups
  1. GSK Faculty (22470)
  2. Sloan Kettering Institute Faculty (11482)
  3. Department of Medicine (10530)
  4. Tow Center for Developmental Oncology (TCDO) (6948)
  5. Sloan Kettering Institute Postdocs (6210)
  6. Solid Tumor Oncology Division (5880)

More Groups

People
  1. Marc Ladanyi (1327)
  2. Steven Larson (957)
  3. Jedd Wolchok (905)
  4. Cristina Antonescu (895)
  5. Kenneth Offit (788)
  6. David Solit (779)

More People

Years
  1. 2025 (298)
  2. 2024 (868)
  3. 2023 (1016)
  4. 2022 (1152)
  5. 2021 (1088)
  6. 2020 (1257)

More Years

Publications
  1. Blood (1470)
  2. Journal of Clinical Oncology (1279)
  3. Cancer Research (1104)
  4. Clinical Cancer Research (527)
  5. Modern Pathology (494)
  6. Journal of Nuclear Medicine (474)

More Publications

Publishers
  1. Nature Publishing Group (2594)
  2. American Association for Cancer Research (2194)
  3. Elsevier Inc. (1937)
  4. American Society of Hematology (1553)
  5. Cell Press (1421)
  6. American Society of Clinical Oncology (1379)

More Publishers

Results (22470)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Safety of reduced infusion times for nivolumab plus ipilimumab (N + I) and nivolumab alone (N) in advanced melanoma
    Meeting Abstract

    Martin-Algarra, S.; Haanen, J. B.; Horak, C.; Bhatia, S.; Ribas, A.; Hwu, W. J.; Slingluff, C. L.; Sharfman, W. H.; Callahan, M.; Hodi, F. S.; more...
    Annals of Oncology (2016)

    Fulltext@MSK | Save
  • A phase I study evaluating DLYE5953A, an antibody-drug conjugate targeting the tumor-associated antigen lymphocyte antigen 6 complex locus E (Ly6E), in patients (pts) with solid tumors
    Meeting Abstract

    Modi, S.; Eder, J. P.; Lorusso, P.; Weekes, C.; Chandarlapaty, S.; Tolaney, S. M.; McLaughlin, J.; Camidge, D. R.; Chang, C. W.; Nazzal, D.; more...
    Annals of Oncology (2016)

    Fulltext@MSK | Save
  • PD-L1 expression as a biomarker for nivolumab (NIVO) plus ipilimumab (IPI) and NIVO alone in advanced melanoma (MEL): A pooled analysis
    Meeting Abstract

    Long, G. V.; Larkin, J.; Ascierto, P. A.; Hodi, F. S.; Rutkowski, P.; Sileni, V.; Hassel, J.; Lebbe, C.; Pavlick, A. C.; Wagstaff, J.; more...
    Annals of Oncology (2016)

    Fulltext@MSK | Save
  • Clinical next generation sequencing (NGS) of esophagogastric (EG) adenocarcinomas identifies distinct molecular signatures of response to HER2 inhibition, first-line 5FU/platinum and PD1/CTLA4 blockade
    Meeting Abstract

    Janjigian, Y. Y.; Sanchez-Vega, F.; Jonsson, P.; Tuvy, Y.; Bouvier, N.; Riches, J.; Kundra, R.; Ku, G.; Hechtman, J. F.; Kelsen, D.; more...
    Annals of Oncology (2016)

    Fulltext@MSK | Save
  • Phase II study of single agent buparlisib in recurrent/refractory primary (PCNSL) and secondary CNS lymphoma (SCNSL)
    Meeting Abstract

    Grommes, C.; Pentsova, E.; Nolan, C.; Wolfe, J.; Mellinghoff, I. K.; Deangelis, L.
    Annals of Oncology (2016)

    Fulltext@MSK | Save
  • Phase I/II study of single agent ibrutinib in recurrent/refractory primary (PCNSL) and secondary CNS lymphoma (SCNSL)
    Meeting Abstract

    Grommes, C.; Gavrilovic, I.; Kaley, T.; Nolan, C.; Omuro, A.; Wolfe, J.; Pentsova, E.; Hatzoglou, V.; Mellinghoff, I. K.; Deangelis, L.
    Annals of Oncology (2016)

    Fulltext@MSK | Save
  • Ipilimumab (IPI) vs placebo (PBO) after complete resection of stage III melanoma: Final overall survival results from the EORTC 18071 randomized, double-blind, phase 3 trial
    Meeting Abstract

    Eggermont, A. M. M.; Chiarion-Sileni, V.; Grob, J. J.; Dummer, R.; Wolchok, J. D.; Schmidt, H.; Hamid, O.; Robert, C.; Ascierto, P. A.; Richards, J. M.; more...
    Annals of Oncology (2016)

    Fulltext@MSK | Save
  • Neoadjuvant anti-PD1, nivolumab, in early stage resectable non-small-cell lung cancer
    Meeting Abstract

    Forde, P. M.; Smith, K. N.; Chaft, J. E.; Hellmann, M.; Merghoub, T.; Wolchok, J. D.; Yang, S. C.; Battafarano, R. J.; Gabrielson, E.; Georgiades, C. S.; more...
    Annals of Oncology (2016)

    Fulltext@MSK | Save
  • A phase 1/2 trial of a monoclonal antibody targeting fucosyl GM1 in relapsed/refractory small cell lung cancer (SCLC): Safety and preliminary efficacy
    Meeting Abstract

    Chu, Q. S. C.; Markman, B.; Leighl, N.; Krug, L.; Rudin, C.; Lathers, D.; Basciano, P.; Fracasso, P. M.; Kollia, G.; Phillips, P.; more...
    Annals of Oncology (2016)

    Fulltext@MSK | Save
  • Preliminary safety and clinical activity of erlotinib plus atezolizumab from a Phase Ib study in advanced NSCLC
    Meeting Abstract

    Ma, B. B. Y.; Rudin, C. M.; Cervantes, A.; Dowlati, A.; Costa, D.; Schmid, P.; Heist, R.; Villaflor, V. M.; Sarkar, I.; Huseni, M. A.; more...
    Annals of Oncology (2016)

    Fulltext@MSK | Save